pyrroles has been researched along with Astrocytoma, Grade IV in 56 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (1.79) | 18.2507 |
2000's | 10 (17.86) | 29.6817 |
2010's | 41 (73.21) | 24.3611 |
2020's | 4 (7.14) | 2.80 |
Authors | Studies |
---|---|
Brahm, CG; de Goeij-de Haas, R; De Witt Hamer, PC; Dekker, H; Henneman, AA; Honeywell, RJ; Hovinga, KE; Jiménez, CR; Knol, JC; Labots, M; Peters, GJ; Pham, TV; Piersma, SR; van Linde, ME; Vandertop, WP; Verheul, HMW | 1 |
Fermi, V; Herold-Mende, C; Regulska, E; Romero-Nieto, C; Rominger, F; Wessling, P; Wolfram, A | 1 |
Bai, R; Biagioni, S; Cavallini, C; Coluccia, A; Coluccia, AML; Da Pozzo, E; Hamel, E; La Regina, G; Liu, T; Martini, C; Mazzoccoli, C; Mazzoni, C; Nalli, M; Orlando, V; Puxeddu, M; Shen, H; Silvestri, R | 1 |
Mason, WP; Richardson, PG; Roth, P; Weller, M | 1 |
Burghardt, I; Papa, E; Szabó, E; Ventura, E; Weiss, T; Weller, M | 1 |
Boger, DL; Boyle, KE; Vazquez, M; Wroe, A | 1 |
Agati, R; Bartolini, S; Brandes, AA; Di Battista, M; Franceschi, E; Genestreti, G; Lamberti, G; Minichillo, S; Mura, A; Paccapelo, A | 1 |
Baeza-Kallee, N; Cappaï, J; Chocry, M; Colin, C; Figarella-Branger, D; Kovacic, H; Lafitte, D; Nuccio, C; Quillien, V; Raujol, J; Rougon, G; Soubéran, A; Tchoghandjian, A | 1 |
Deng, Q; Huang, Y; Lee, CS; Li, S; Li, X; Liu, F; Liu, Z; Qing, W; Wang, H | 1 |
Lei, C; Shuyun, H; Xiangrong, C; Yiquan, K; Yongjun, Y; Zhilin, Y | 1 |
Bonezzi, K; Borsotti, P; Cvitkovic, E; D'Incalci, M; Frapolli, R; Giavazzi, R; Noel, K; Sala, F; Taraboletti, G; Ubezio, P; Zangarini, M; Zucchetti, M | 1 |
Buchroithner, J; Capper, D; Embacher, S; Gotwald, T; Haybaeck, J; Herrlinger, U; Holzner, B; Hutterer, M; Marosi, C; Moik, M; Nowosielski, M; Oberndorfer, S; Preusser, M; Seiz, M; Stockhammer, F; Stockhammer, G; Tuettenberg, J; Vajkoczy, P; Wick, A | 1 |
Balaña, C; Capellades, J; Gallego, O; Gil, MJ; Gonzalez, S; Perez, P; Reynes, G; Ribalta, T; Verger, E | 1 |
Jia, B; Liu, H; Liu, Z; Ma, T; Shi, J; Sun, X; Wang, F; Wu, Y; Yu, X; Zhao, H | 1 |
Burrell, K; Chung, C; Foltz, W; Hill, R; Jalali, S; Singh, S; Zadeh, G | 1 |
Bao, X; Wang, MW; Zhang, YJ; Zhang, YP | 1 |
Coquerel, B; Demange, E; Kassim, Y; Le Cerf, D; Perrot, V; Petit, A; Simon, T; Vannier, JP | 1 |
Corbacioglu, S; Debatin, KM; Engelke, J; Fulda, S; Halatsch, ME; Karpel-Massler, G; Nonnenmacher, L; Simmet, T; Westhoff, MA | 1 |
Barnhart, TE; Cai, W; Chen, F; Goel, S; Hernandez, R; Hong, H; Shi, S; Valdovinos, HF | 1 |
Cheng, SY; Feng, H; Gao, WQ; Hou, Y; Hu, B; James, CD; Li, Y; Li, Z; Parsa, AT; Raizer, JJ; Sarkaria, JN; Xie, B; Yin, Y; Zhang, L; Zhang, W | 1 |
Huo, L; Jiang, B; Liu, H; Liu, J; Liu, Z; Lu, J | 1 |
Martinho, O; Reis, RM; Zucca, LE | 1 |
Cardoso, AL; Costa, PM; Cunha, P; Custódia, C; Pedroso de Lima, MC; Pereira de Almeida, L | 1 |
Butowski, N; Cloughesy, TF; Colman, H; De Groot, JF; Haidar, S; Hsu, HH; Huse, J; Ligon, KL; Marimuthu, A; Molinaro, AM; Nayak, L; Nolop, KB; Omuro, AM; Perry, A; Phillips, J; Prados, M; Wen, PY; West, BL | 1 |
Bailey, CP; Bouchier-Hayes, L; Chandra, J; Johnson, B; Manton, CA; Singh, M | 1 |
Baeza-Kallee, N; Colin, C; Denicolaï, E; El-Battari, A; Figarella-Branger, D; Jiguet-Jiglaire, C; Soubéran, A; Tabouret, E; Tchoghandjian, A; Villard, C | 1 |
Jiang, X; Qi, B; Wang, Z; Xia, H; Zhou, T | 1 |
Burbidge, S; Colapietro, A; Delle Monache, S; Festuccia, C; Gravina, GL; Mancini, A; Marampon, F; Patient, L; Richardson, PJ; Sferra, R; Vitale, F | 1 |
Rivera-Delgado, E; von Recum, HA | 1 |
de Barros e Silva, MJ; de Paiva, TF; Fanelli, MF; Gimenes, DL; Rinck, JA | 1 |
Czabanka, M; Heppner, F; Ullrich, A; Vajkoczy, P; Vinci, M | 1 |
Abdulkarim, B; Aghi, M; Chahal, M; Christensen, JG; Famulski, K; Graham, K; Jacques, A; Lesniak, D; Murray, D; Sabri, S; Xu, Y | 1 |
Gariboldi, MB; Monti, E; Ravizza, R | 1 |
Jane, EP; Pollack, IF; Premkumar, DR | 1 |
Argyriou, AA; Dimitropoulos, K; Giannopoulou, E; Kalofonos, HP; Petsas, T; Tsiata, E; Zolota, V | 1 |
Beer, AJ; Schwaiger, M | 1 |
Allen, L; Barnett, J; Battle, MR; Goggi, JL; Morrison, MS | 1 |
Bielen, A; Box, GM; de Haven Brandon, A; Eccles, SA; Gowan, S; Hargrave, D; Hofmann, F; Jeay, S; Jones, C; Jury, A; Martins, V; Perryman, L; Popov, S; Raynaud, FI; Valenti, M | 1 |
Han, N; Hauser, K; Herion, TW; Huber, PE; Lahn, M; Peschke, P; Timke, C; Weber, KJ; Wirkner, U; Zhang, M | 1 |
Debus, J; Han, N; Huber, PE; Kleber, S; Lahn, M; Martin-Villalba, A; Peschke, P; Röhrich, M; Timke, C; Tuettenberg, J; Wirkner, U; Zhang, M | 1 |
Cho, G; Kang, JS; Kang, MR; Kim, JK; Kim, YR; Lee, CK; Park, SB; Song, Y; Suh, JY | 1 |
Bruce, JN; Canoll, P; Christensen, JG; Crisman, C; D'Amico, R; Ebiana, V; Gil, O; Kennedy, BC; Lei, L; Rosenfeld, SS; Sisti, J | 1 |
Barcellos-Hoff, MH; Hardee, ME; Lonning, SM; Marciscano, AE; Medina-Ramirez, CM; Narayana, A; Zagzag, D | 1 |
de Groot, JF; Henry, V; Heymach, JV; Holmes, L; Liang, J; Piao, Y; Zurita, AJ | 1 |
Gallia, GL; Joshi, AD; Loilome, W; Riggins, GJ; Siu, IM; Tyler, B | 1 |
Fine, HA; Iwamoto, FM; Kreisl, TN; Salgado, C; Shih, JH; Smith, P; Sul, J | 1 |
Bruce, JN; Canoll, P; Cardoso, AL; Costa, PM; Nóbrega, C; Pedroso de Lima, MC; Pereira de Almeida, LF | 1 |
Fueller, T; Hummel, V; Rieckmann, P; Tonn, JC; Wagner, S | 1 |
Donnelly, E; Geng, L; Hallahan, DE; Himmelfarb, E; McMahon, G; Mendel, D; Schueneman, AJ; Tan, J | 1 |
Abdollahi, A; Bischof, M; Debus, J; Grone, HJ; Hahnfeldt, P; Han, X; Hlatky, L; Huber, PE; Klenke, F; Krix, M; Lipson, KE; Poerschke, D; Roth, A; Sckell, A; Zieher, H | 1 |
Bernsen, HJ; Bussink, J; Peeters, W; Schuuring, J; van Der Kogel, AJ | 1 |
Christensen, JG; de Boüard, S; Gauduchon, P; Guillamo, JS; Herlin, P; Lemoisson, E; Raymond, E | 1 |
Halmos, G; Kiaris, H; Nagy, A; Schally, AV; Sun, B; Szepeshazi, K | 1 |
Hirth, KP; Menger, MD; Schilling, L; Schmiedek, P; Thurnher, A; Ullrich, A; Vajkoczy, P | 1 |
Fong, TA; Hirth, KP; Menger, MD; Schilling, L; Schmiedek, P; Ullrich, A; Vajkoczy, P; Vollmar, B | 1 |
Donnelly, E; Geng, L; Hallahan, DE; Lin, PC; McMahon, G; Oshinka, H; Sierra-Rivera, E | 1 |
1 review(s) available for pyrroles and Astrocytoma, Grade IV
Article | Year |
---|---|
Proteasome inhibition for the treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents; Bortezomib; Brain Neoplasms; Drug Development; Glioblastoma; Humans; Lactones; Proteasome Inhibitors; Pyrroles | 2020 |
4 trial(s) available for pyrroles and Astrocytoma, Grade IV
Article | Year |
---|---|
A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).
Topics: Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Pyrroles; Sunitinib; Survival Rate | 2014 |
Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a phase II study.
Topics: Aged; Antineoplastic Agents; Biopsy; Brain Neoplasms; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Radiotherapy; Sunitinib; Time Factors; Treatment Outcome | 2014 |
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
Topics: Administration, Oral; Aminopyridines; Biomarkers, Tumor; Blood-Brain Barrier; Brain Neoplasms; Cohort Studies; Female; Follow-Up Studies; Glioblastoma; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Tissue Distribution; Tumor Burden | 2016 |
Continuous daily sunitinib for recurrent glioblastoma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Pyrroles; Quality of Life; Sunitinib; Survival Rate | 2013 |
51 other study(ies) available for pyrroles and Astrocytoma, Grade IV
Article | Year |
---|---|
Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Indoles; Proteomics; Pyrroles; Sunitinib | 2022 |
Luminescent Pyrrole-Based Phosphaphenalene Gold Complexes: Versatile Anticancer Tools with Wide Applicability.
Topics: Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Gold; Humans; Luminescence; Pyrroles | 2022 |
Structure-activity relationship studies and in vitro and in vivo anticancer activity of novel 3-aroyl-1,4-diarylpyrroles against solid tumors and hematological malignancies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Glioblastoma; Hematologic Neoplasms; Humans; Injections, Intraperitoneal; Injections, Subcutaneous; Mice; Mice, Inbred BALB C; Molecular Structure; Optical Imaging; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma.
Topics: Antineoplastic Agents; Butadienes; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Hepatocyte Growth Factor; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Pteridines; Pyrazoles; Pyridazines; Pyrimidines; Pyrroles; Quinolines; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta | 2017 |
Duocarmycin SA, a potent antitumor antibiotic, sensitizes glioblastoma cells to proton radiation.
Topics: Antibiotics, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Duocarmycins; Glioblastoma; Humans; Indoles; Necrosis; Protons; Pyrroles; Radiation-Sensitizing Agents | 2018 |
Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?
Topics: Acetanilides; Adult; Aged; Antineoplastic Agents, Immunological; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Quinolines; Retreatment; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2018 |
Inhibitor of Apoptosis Proteins Determines Glioblastoma Stem-Like Cell Fate in an Oxygen-Dependent Manner.
Topics: Adaptor Proteins, Signal Transducing; Adrenomedullin; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Brain Neoplasms; Carbonic Anhydrase IX; Cell Differentiation; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cyclohexanes; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Inhibitor of Apoptosis Proteins; Neoplasm Proteins; Neoplastic Stem Cells; Oxygen; Pyrroles; Signal Transduction; Spheroids, Cellular; Tissue Culture Techniques; X-Linked Inhibitor of Apoptosis Protein | 2019 |
Bis-diketopyrrolopyrrole conjugated polymer nanoparticles as photothermic nanoagonist for specific and synergistic glioblastoma therapy.
Topics: Animals; Cell Line, Tumor; Female; Glioblastoma; Humans; Hyperthermia, Induced; Ketones; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Phototherapy; Pyrroles | 2019 |
Atorvastatin suppresses glioma invasion and migration by reducing microglial MT1-MMP expression.
Topics: Atorvastatin; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Signaling System; Matrix Metalloproteinase 14; Matrix Metalloproteinase 2; Microglia; Neoplasm Invasiveness; p38 Mitogen-Activated Protein Kinases; Pyrroles | 2013 |
Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Calixarenes; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endothelial Cells; Female; Galectin 1; Glioblastoma; Half-Life; Humans; Indoles; Inhibitory Concentration 50; Mice; Mice, Nude; Molecular Targeted Therapy; Ovarian Neoplasms; Pyrroles; Sunitinib; Tissue Distribution; Xenograft Model Antitumor Assays | 2013 |
Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin αvβ3 and vascular endothelial growth factor.
Topics: Animals; Colonic Neoplasms; Fluorescent Dyes; Glioblastoma; HT29 Cells; Humans; Indoles; Infrared Rays; Integrin alphaVbeta3; Longitudinal Studies; Mice; Molecular Targeted Therapy; Neovascularization, Pathologic; Optical Imaging; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Glioblastoma; Humans; Image Processing, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Mice; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sunitinib | 2014 |
Early monitoring antiangiogenesis treatment response of Sunitinib in U87MG Tumor Xenograft by (18)F-FLT MicroPET/CT imaging.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dideoxynucleosides; Drug Monitoring; Early Detection of Cancer; Female; Glioblastoma; Indoles; Mice; Mice, Inbred C57BL; Mice, Nude; Multimodal Imaging; Positron-Emission Tomography; Pyrroles; Radiopharmaceuticals; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Direct effect of bevacizumab on glioblastoma cell lines in vitro.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autocrine Communication; Bevacizumab; Brain Neoplasms; Calcium Signaling; Cell Culture Techniques; Cell Division; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Hyaluronic Acid; Hydrogels; Indoles; MAP Kinase Signaling System; Neoplasm Invasiveness; Neoplasm Proteins; Placenta Growth Factor; Pregnancy Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
RIST: a potent new combination therapy for glioblastoma.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Child; Dacarbazine; Female; Glioblastoma; Humans; Indoles; Irinotecan; Male; Membrane Potential, Mitochondrial; Mice, Inbred NOD; Molecular Targeted Therapy; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
VEGF₁₂₁-conjugated mesoporous silica nanoparticle: a tumor targeted drug delivery system.
Topics: Animals; Drug Delivery Systems; Glioblastoma; Glioma; Humans; Indoles; Mice; Nanoparticles; Pyrroles; Silicon Dioxide; Sunitinib; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays | 2014 |
Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived-growth factor receptor α.
Topics: Animals; Brain Neoplasms; Carbazoles; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclic AMP-Dependent Protein Kinases; Female; Glioblastoma; HEK293 Cells; Humans; Isoquinolines; Mice; Phosphorylation; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyrroles; rac GTP-Binding Proteins; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; Sulfonamides | 2015 |
Synthetic miR-145 Mimic Enhances the Cytotoxic Effect of the Antiangiogenic Drug Sunitinib in Glioblastoma.
Topics: Angiogenesis Inhibitors; Apoptosis; Cell Line; Glioblastoma; Humans; Indoles; MicroRNAs; Pyrroles; Sunitinib | 2015 |
AXL as a modulator of sunitinib response in glioblastoma cell lines.
Topics: Angiogenesis Inhibitors; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; ErbB Receptors; Gene Knockdown Techniques; Glioblastoma; Heterocyclic Compounds, 3-Ring; Humans; Indoles; Proto-Oncogene Proteins; Pyrroles; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sunitinib | 2015 |
MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Chemotherapy, Adjuvant; Drug Carriers; Gene Expression Regulation, Neoplastic; Glioblastoma; Indoles; Male; Mice, Inbred C57BL; MicroRNAs; Nanomedicine; Nanoparticles; Oligonucleotides, Antisense; Protein Kinase Inhibitors; Pyrroles; rhoB GTP-Binding Protein; RNAi Therapeutics; Scorpion Venoms; Sunitinib; Technology, Pharmaceutical; Time Factors; Tumor Burden | 2015 |
Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Bortezomib; Caspases; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Lactones; Mice; Proliferating Cell Nuclear Antigen; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrroles | 2016 |
Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152.
Topics: Adult; Aged; Aged, 80 and over; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromatography; Cyclohexanes; Glioblastoma; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Paraffin Embedding; Prognosis; Pyrroles; Tissue Fixation; Young Adult | 2016 |
HSP47 Promotes Glioblastoma Stemlike Cell Survival by Modulating Tumor Microenvironment Extracellular Matrix through TGF-β Pathway.
Topics: Analysis of Variance; Animals; Brain Neoplasms; Cell Survival; Computational Biology; Disease Models, Animal; Extracellular Matrix; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glioblastoma; HSP47 Heat-Shock Proteins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Platelet Endothelial Cell Adhesion Molecule-1; Pyrazoles; Pyrroles; RNA, Messenger; Transforming Growth Factor beta; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2017 |
The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain; Brain Neoplasms; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Interactions; Drug Synergism; Glioblastoma; Heterografts; Humans; Indoles; Mice; Pyrroles; Receptors, CXCR4; Sunitinib | 2017 |
Using Affinity To Provide Long-Term Delivery of Antiangiogenic Drugs in Cancer Therapy.
Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cellulose; Cyclodextrins; Drug Delivery Systems; Estradiol; Female; Glioblastoma; Humans; Indoles; Mice; Mice, Nude; ortho-Aminobenzoates; Pyrroles; Silybin; Silymarin | 2017 |
Tuberculosis in a patient on temozolomide: a case report.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antibiotics, Antitubercular; Anticholesteremic Agents; Anticonvulsants; Antineoplastic Agents, Alkylating; Atorvastatin; Brain Neoplasms; Combined Modality Therapy; Cyclosporine; Dacarbazine; Dexamethasone; Female; Fluoxetine; Glioblastoma; Heptanoic Acids; Humans; Immunosuppressive Agents; Isoniazid; Middle Aged; Omeprazole; Phenobarbital; Prednisone; Pyrazinamide; Pyrroles; Radiotherapy; Red-Cell Aplasia, Pure; Rifampin; Temozolomide; Trimethoprim, Sulfamethoxazole Drug Combination; Tuberculosis, Pulmonary | 2009 |
Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Division; Cell Line, Tumor; Desmin; Doxorubicin; Glioblastoma; Hemodynamics; Indoles; Mice; Mice, Nude; Microcirculation; Pyrroles; Sunitinib | 2009 |
MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Separation; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression; Gene Expression Profiling; Glioblastoma; Humans; Indoles; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Radiotherapy; Reverse Transcriptase Polymerase Chain Reaction; Sunitinib; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2010 |
The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells.
Topics: Angiogenesis Inhibitors; Cell Line, Tumor; Cell Survival; Drug Synergism; Glioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin-Like Growth Factor I; Pyrimidines; Pyrroles; Receptor, IGF Type 1; STAT3 Transcription Factor | 2010 |
Co-administration of NVP-AEW541 and dasatinib induces mitochondrial-mediated apoptosis through Bax activation in malignant human glioma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Cell Cycle; Cell Cycle Proteins; Cell Growth Processes; Cell Line, Tumor; Dasatinib; Drug Synergism; Fluorescent Antibody Technique; Glioblastoma; Humans; Mitochondria; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; Thiazoles; Transfection | 2010 |
The effects of anti-VEGFR and anti-EGFR agents on glioma cell migration through implication of growth factors with integrins.
Topics: Cell Line, Tumor; Cell Movement; ErbB Receptors; Focal Adhesion Kinase 1; Glioblastoma; Humans; Indoles; Integrin beta1; Integrin beta3; Integrins; Lapatinib; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib; Vascular Endothelial Growth Factor Receptor-1 | 2010 |
PET of αvbeta3-integrin and αvbeta5-integrin expression with 18F-fluciclatide for assessment of response to targeted therapy: ready for prime time?
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Glioblastoma; Humans; Indoles; Integrin alphaVbeta3; Male; Mice; Mice, Nude; Peptides; Polyethylene Glycols; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Vitronectin; Reproducibility of Results; Sensitivity and Specificity; Sunitinib | 2011 |
Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVbeta3-integrin and αV beta5-integrin imaging agent.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Glioblastoma; Humans; Indoles; Integrin alphaVbeta3; Male; Mice; Mice, Nude; Peptides; Polyethylene Glycols; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Vitronectin; Reproducibility of Results; Sensitivity and Specificity; Sunitinib | 2011 |
Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Child; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Mice, Nude; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.
Topics: Angiopoietin-1; Angiopoietin-2; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Cells, Cultured; Combined Modality Therapy; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Immunohistochemistry; Ki-67 Antigen; Mice; Mice, Inbred BALB C; Mice, Nude; Platelet Endothelial Cell Adhesion Molecule-1; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Radiotherapy; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA Repair; Glioblastoma; Humans; Mesenchymal Stem Cells; Mice; Mice, Inbred BALB C; Mice, SCID; Microarray Analysis; Neoplasm Invasiveness; Neoplastic Stem Cells; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Radiation Tolerance; Radiation-Sensitizing Agents; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad2 Protein; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2011 |
Is apparent diffusion coefficient reliable and accurate for monitoring effects of antiangiogenic treatment in a longitudinal study?
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Diffusion Magnetic Resonance Imaging; Female; Glioblastoma; Image Enhancement; Image Interpretation, Computer-Assisted; Indoles; Longitudinal Studies; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Treatment Outcome | 2012 |
The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Disease Models, Animal; Disease Progression; Glioblastoma; Indoles; Mice; Mice, Transgenic; Pyrroles; Radiation Dosage; Sunitinib | 2012 |
Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β.
Topics: Animals; Antibodies, Neutralizing; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; DNA Damage; DNA, Neoplasm; Female; Glioblastoma; Humans; Mice; Mice, Inbred C57BL; Mink; Neoplastic Stem Cells; Neural Stem Cells; Pyrazoles; Pyrroles; Radiation Tolerance; Radiation-Sensitizing Agents; Signal Transduction; Transforming Growth Factor beta; Tumor Microenvironment | 2012 |
Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Hypoxia; Cell Line, Tumor; Drug Resistance, Neoplasm; Flow Cytometry; Glioblastoma; Humans; Immunohistochemistry; Indoles; Mesoderm; Mice; Mice, Nude; Myeloid Cells; Neovascularization, Pathologic; Phenotype; Pyrroles; Real-Time Polymerase Chain Reaction; Receptors, Vascular Endothelial Growth Factor; Stem Cells; Sunitinib; Tumor Microenvironment; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Drug Synergism; Female; Gefitinib; Glioblastoma; Humans; Immunoblotting; Indoles; Inhibitory Concentration 50; Mice; Mice, Nude; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Rats, Inbred F344; Spheroids, Cellular; Sunitinib; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis Regulatory Proteins; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Indoles; Mice; MicroRNAs; PTEN Phosphohydrolase; Pyrroles; RNA-Binding Proteins; Signal Transduction; Sunitinib; Up-Regulation | 2013 |
Influence of VEGF-R2 inhibition on MMP secretion and motility of microvascular human cerebral endothelial cells (HCEC).
Topics: Angiogenesis Inhibitors; Brain Neoplasms; Cell Movement; Cerebral Cortex; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Glioblastoma; Humans; Immunoenzyme Techniques; In Vitro Techniques; Indoles; Interleukin-10; Matrix Metalloproteinases; Microcirculation; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Pyrroles; Spheroids, Cellular; Tumor Cells, Cultured; Umbilical Veins; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Lewis Lung; Combined Modality Therapy; Endothelium, Vascular; Glioblastoma; Humans; Indoles; Mice; Mice, Inbred C57BL; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neovascularization, Pathologic; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2003 |
Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Movement; Cell Survival; Drug Synergism; Endostatins; Endothelium, Vascular; Female; Glioblastoma; Humans; Indoles; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrroles; Ultrasonography; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2003 |
Irradiation combined with SU5416: microvascular changes and growth delay in a human xenograft glioblastoma tumor line.
Topics: Angiogenesis Inhibitors; Animals; Cell Hypoxia; Cell Line, Tumor; Combined Modality Therapy; Dose-Response Relationship, Radiation; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Indoles; Mice; Mice, Inbred BALB C; Mice, Nude; Microcirculation; Necrosis; Pyrroles; Recurrence; Remission Induction; Transplantation, Heterologous | 2005 |
Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Blotting, Western; Brain; Brain Neoplasms; Cell Line, Tumor; Flow Cytometry; Focal Adhesion Protein-Tyrosine Kinases; Glioblastoma; Humans; Immunohistochemistry; Immunoprecipitation; Indoles; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; Organ Culture Techniques; Phosphorylation; Pyrroles; src-Family Kinases; Sunitinib; Xenograft Model Antitumor Assays | 2007 |
Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.
Topics: Animals; Antibiotics, Antineoplastic; Body Weight; Cell Survival; Doxorubicin; Glioblastoma; Humans; Male; Mice; Mice, Nude; Octreotide; Pyrroles; Transfection; Tumor Cells, Cultured | 2000 |
Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications.
Topics: Analysis of Variance; Angiogenesis Inhibitors; Animals; Disease Models, Animal; Endothelial Growth Factors; Enzyme Inhibitors; Glioblastoma; Indoles; Lymphokines; Male; Mice; Mice, Nude; Microcirculation; Microscopy, Fluorescence; Microscopy, Video; Neoplasm Transplantation; Neovascularization, Pathologic; Protein Isoforms; Protein-Tyrosine Kinases; Pyrroles; Rats; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Mitogen; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Skin Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy.
Topics: Animals; Antineoplastic Agents; Enzyme Inhibitors; Glioblastoma; Indoles; Male; Mice; Mice, Nude; Microcirculation; Neovascularization, Pathologic; Pyrroles; Rats; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor | 1999 |
Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.
Topics: Angiogenesis Inhibitors; Animals; Cell Survival; Dose-Response Relationship, Radiation; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Inhibitors; Glioblastoma; Indoles; Lymphokines; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pyrroles; Radiation Tolerance; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |